tDCS for Schizophrenia and Schizoaffective Disorder

Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia

Recruiting Observational Study
Schizophrenia Schizoaffective
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
20 (estimated)
Sponsor
Centre for Addiction and Mental Health · Other
Who this trial is looking for

This trial is looking for patients with schizophrenia or schizoaffective disorder to study brain changes using a technique called tDCS. Participants will need to already be involved in a related study and meet certain health criteria.

Are You a Good Fit for This Trial?
Rules you out Severe thought disorderRecent substance dependence

You may be able to join if

  • I am at least 18 years old
  • I have been diagnosed with schizophrenia or schizoaffective disorder
  • I can consent to participate in this study
  • I have been on stable oral antipsychotic medication for at least 2 months

You may not be able to join if

  • I am unable to consent to the study
  • I have unstable medical or neurological illnesses
  • I have acute suicidal or homicidal thoughts
  • I have serious thought disturbances
  • I have a recent substance dependence issue
  • I have a positive drug test result
  • I have metal implants or a pacemaker
  • I am pregnant

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia. Synaptic density levels will be measured using a novel positron emission tomography (PET) radiotracer \[18F\]SDM-8, which is currently the best-in-class method to quantify synaptic density in humans. This will be a companion study to a parent study b…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Enrolment in the tDCS-adherence parent study (REB# 103-2018). The parent study inclusion criteria are: 1. Male or female participants of any race or ethnicity 2. Inpatients or outpatients ≥18 years of age 3. DSM-V diagnosis of schizophrenia or schizoaffective disorder 4. Capabl…
Contacts

Philip Gerretsen, MD, PhD

416-535-8501

philip.gerretsen@camh.ca

CONTACT

Ariel Graff, MD, PhD

416-535-8501

ariel.graff@camh.ca

CONTACT